StockMacro
Menu

Sana Biotechnology

$1.59 -48% in 6 monthsMarket cap $476.4M

SANA on XNAS, Health Care, Sana Biotechnology, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 51% in a year while the company lost $149.3M over 12 months.

  • BadShort interest 14% of shares, 15.8 days to cover
  • WatchNews coverage 4.0 times its usual week, eight articles

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
142
Website
sana.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 2 Mar 2027 (an estimate: a year ago it reported on 3 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net income $20.4M.
Quarter to 31 Dec 2021: revenue –, net income -$110.7MQuarter to 31 Mar 2022: revenue –, net income -$31.4MQuarter to 30 Jun 2022: revenue –, net income -$72.5MQuarter to 30 Sep 2022: revenue –, net income -$85.1MQuarter to 31 Dec 2022: revenue –, net income -$80.4MQuarter to 31 Mar 2023: revenue –, net income -$82.1MQuarter to 30 Jun 2023: revenue –, net income -$114.0MQuarter to 30 Sep 2023: revenue –, net income $984KQuarter to 31 Dec 2023: revenue –, net income -$88.1MQuarter to 31 Mar 2024: revenue –, net income -$107.5MQuarter to 30 Jun 2024: revenue –, net income -$50.3MQuarter to 30 Sep 2024: revenue –, net income -$59.9MQuarter to 31 Dec 2024: revenue –, net income -$49.1MQuarter to 31 Mar 2025: revenue –, net income -$49.4MQuarter to 30 Jun 2025: revenue –, net income -$93.8MQuarter to 30 Sep 2025: revenue –, net income -$42.2MQuarter to 31 Dec 2025: revenue –, net income -$58.8MQuarter to 31 Mar 2026: revenue –, net income -$47.2MQuarter to 30 Jun 2026: revenue –, net income -$63.6MQuarter to 30 Sep 2026: revenue –, net income $20.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $114.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–$20.4M
30 Jun 2026–-$63.6M
31 Mar 2026–-$47.2M
31 Dec 2025–-$58.8M
30 Sep 2025–-$42.2M
30 Jun 2025–-$93.8M
31 Mar 2025–-$49.4M
31 Dec 2024–-$49.1M
30 Sep 2024–-$59.9M
30 Jun 2024–-$50.3M
31 Mar 2024–-$107.5M
31 Dec 2023–-$88.1M
30 Sep 2023–$984K
30 Jun 2023–-$114.0M
31 Mar 2023–-$82.1M
31 Dec 2022–-$80.4M
30 Sep 2022–-$85.1M
30 Jun 2022–-$72.5M
31 Mar 2022–-$31.4M
31 Dec 2021–-$110.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$149.3M -$234.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.53 -$0.97
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -79.5% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $121.7M $153.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$121.7M (net cash) -$153.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.60
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.6 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Sana BiotechnologySANA (this company) $476.4Mloss–––
RegenxbioRGNX $473.4Mloss3.1-4.6%-114%
Ginkgo BioworksDNA $483.5Mloss4.8-33%-249%
Fennec PharmaceuticalsFENC $462.1M2287.0+71%3.1%
Electra TherapeuticsETRA $509.8M––––
IRulya TherapeuticsIRLA $432.4Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-3.8%

200 13F filers vs 208

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

77%

229.4M shares held by 13F filers (30 Sep 2026) of 299.6M outstanding (29 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

14%

40.6M shares sold short (30 Oct 2026) of 299.6M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

15.8

40.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-0.6%

40.8M shares sold short in the report before, 40.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

61%

61% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

7

7 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.5×

7 articles in the last 7 days; its usual week has 2.

Price $1.59 on 20 Nov 2026, -51% over 12 months (12-month range $1.59 to $5.18)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: -$1.9M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 6 published in the last 12 months, 0% on the 12 months before.
Capital spending per quarter. Capital spending $791K in the latest quarter, +1829% on a year earlier.
Institutional holders (13F filers). 200 13F filers reported holding it in the latest 13F quarter, +16% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
24 Apr 20268-K and other filingsDirector or officer change
17 Feb 20268-K and other filingsDirector or officer change
17 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Sep 20258-K and other filingsDirector or officer change
29 Aug 20258-K and other filingsDirector or officer change
29 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Jan 2025Sharp changeShort interest spike: short interest spike, 50.3M vs usual 27.3M (2025-01-15); 2.5x the same period a year earlier
8 Oct 20248-K and other filingsDirector or officer change
12 Sep 20248-K and other filingsDirector or officer change
12 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 36 vs usual 13 (2024-03-31); 3.3x the same period a year earlier
14 May 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 15.8M vs usual 4.4M (2024-03-31); 7.3x the same period a year earlier
18 Apr 20248-K and other filingsDirector or officer change
18 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Mar 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 14.0M vs usual 4.4M (2023-12-31); 3.1x the same period a year earlier
10 Oct 20238-K and other filingsRestructuring costs announced
21 Aug 20238-K and other filingsA major agreement ended
28 Apr 20238-K and other filingsDirector or officer change
10 Apr 20238-K and other filingsDirector or officer change
10 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Nov 20228-K and other filingsRestructuring costs announced
17 May 2022Sharp changeShort interest spike: short interest spike, 18.0M vs usual 7.6M (2022-04-29); 5.0x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 17.7M vs usual 7.0M (2022-04-14); 5.3x the same period a year earlier
Insider net buying (open market)
Month from 1 Feb 2022: -$2K published
Month from 1 Mar 2022: $204K published
Month from 1 Feb 2023: $500K published
Month from 1 May 2023: -$3.5M published
Month from 1 Jun 2023: -$2.5M published
Month from 1 Dec 2023: -$300K published
Month from 1 Feb 2024: $10.0M published
Month from 1 Mar 2024: -$236K published
Month from 1 Sep 2024: -$1.2M published
Month from 1 Jan 2025: -$1.9M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 5 published
Quarter from 1 Apr 2022: 16 published
Quarter from 1 Jul 2022: 5 published
Quarter from 1 Oct 2022: 5 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Apr 2023: 2 published
Quarter from 1 Jul 2023: 6 published
Quarter from 1 Oct 2023: 6 published
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Apr 2024: 2 published
Quarter from 1 Jul 2024: 9 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 4 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Jul 2026: 4 published
Quarter from 1 Oct 2026: 2 published
Capital spending per quarter
Quarter ended 31 Dec 2020: $9.3M; public on 17 Mar 2022
Quarter ended 31 Dec 2021: $5.2M, -44% on a year earlier; public on 17 Mar 2022
Quarter ended 31 Mar 2022: $7.5M, +17% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $4.4M, -57% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $4.3M, -46% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $4.6M, -12% on a year earlier; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $2.2M, -71% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $1.6M, -64% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $2.2M, -49% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $14.0M, +205% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $15.8M, +628% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $13.1M, +728% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $4.1M, +83% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Mar 2025: $136K, -99% on a year earlier; public on 9 May 2025
Quarter ended 30 Sep 2025: $41K, -99% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $288K, +112% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $1.6M; public on 11 Aug 2026
Quarter ended 30 Sep 2026: $791K, +1829% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 95; public on 14 Feb 2022
31 Mar 2022 report: 109; public on 16 May 2022
30 Jun 2022 report: 110; public on 15 Aug 2022
30 Sep 2022 report: 114; public on 14 Nov 2022
31 Dec 2022 report: 110; public on 14 Feb 2023
31 Mar 2023 report: 114; public on 15 May 2023
30 Jun 2023 report: 113; public on 14 Aug 2023
30 Sep 2023 report: 122; public on 14 Nov 2023
31 Dec 2023 report: 121; public on 14 Feb 2024
31 Mar 2024 report: 146; public on 15 May 2024
30 Jun 2024 report: 136; public on 14 Aug 2024
30 Sep 2024 report: 148; public on 14 Nov 2024
31 Dec 2024 report: 163; public on 14 Feb 2025
31 Mar 2025 report: 157; public on 15 May 2025
30 Jun 2025 report: 149; public on 14 Aug 2025
30 Sep 2025 report: 172; public on 14 Nov 2025
31 Dec 2025 report: 194; public on 17 Feb 2026
31 Mar 2026 report: 196; public on 15 May 2026
30 Jun 2026 report: 208; public on 14 Aug 2026
30 Sep 2026 report: 200; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is net income, quarter at $20.4M (30 Sep 2026), 137% below its normal quarter of -$54.6M; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: -$1.9M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 6 published in the last 12 months, 0% on the 12 months before.
  • Capital spending per quarter: Capital spending $791K in the latest quarter, +1829% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 18 insider trades

No trades in the last 90 days; the latest was filed 10 Jan 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
10 Jan 2025FMR LLC (Fidelity)See Remark 1Sell290,912$6.49$1.9MForm 4
26 Sep 2024Richard MulliganDirectorSellplanned in advance (10b5-1)300,000$3.98$1.2MForm 4
11 Mar 2024Patrick Y YangDirectorSell25,000$9.45$236KForm 4
12 Feb 2024ARCH Venture Fund X, L.P. and 9 others10% ownerBuy1,818,181$5.50$10.0MForm 4
18 Dec 2023Christian HordoEVP, Chief Business OfficerSellplanned in advance (10b5-1)75,000$4.00$300KForm 4
8 Jun 2023Flagship V VentureLabs Rx Fund, L.P. and 3 others10% ownerSell403,758$6.28$2.5MForm 4
26 May 2023Flagship Ventures Fund V General Partner LLC and 3 others10% ownerSell545,242$6.47$3.5MForm 4
17 Feb 2023Joshua H. BilenkerDirectorBuy20,000$25.00$500KForm 4

200 institutions reported shares at the end of Q3 2026, 77% of the shares outstanding; 22 opened a position, 29 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
ARCH Venture Management, LLC45.9M15.3%$133.7MNew+45.9M
FMR LLC (Fidelity)37.3M12.4%$108.7M-136K-0.4%
Flagship Pioneering, LLC25.0M8.34%$72.9MNo change
Ra Capital Management, L.P.18.8M6.26%$54.7MNo change
BlackRock, Inc.16.4M5.47%$47.8M-291K-1.7%
Canada Pension Plan Investment Board10.2M3.41%$29.8M-2,8000%
State Street Corp9.6M3.20%$27.9M-1.6M-14%
Vanguard Capital Management LLC8.6M2.87%$25.1M+236K+2.8%
Geode Capital Management, LLC4.7M1.55%$13.6M-27K-0.6%
Bank of America Corp4.6M1.55%$13.5M-1.1M-19%

Company events

All 26 company events

In 12 months: 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
24 Apr 2026Director or officer change8-K
17 Feb 2026Director or officer change8-K
5 Sep 2025Director or officer change8-K
29 Aug 2025Director or officer change8-K
7 Aug 2025Signed a major agreement8-K
8 Oct 2024Director or officer change8-K
12 Sep 2024Director or officer change8-K
18 Apr 2024Director or officer change8-K

The 5 newest of 166 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

21 May 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Sana Biotechnology (SANA): spent $15.8M on capital projects in the quarter ended 31 Mar 2024, 7.3× the same quarter last year, while it saw 36 13F filers open a new position in the quarter ended 31 Mar 2024, 3.3× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Financials: Quarterly capital spending jump, became public on 14 May 2024
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2024
2022-03-31: $7.5M2022-06-30: $4.4M2022-09-30: $4.3M2022-12-31: $4.6M2023-03-31: $2.2M2023-06-30: $1.6M2023-09-30: $2.2M2023-12-31: $14.0M2024-03-31: $15.8M
The quarter ended 31 Mar 2024 against the 8 quarters before it. this quarterearliernormal: $4.4M
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 14 May 2024

Sana Biotechnology spent $15.8M on capital projects in the quarter ended 31 Mar 2024, 7.3× the same quarter last year.

This period
$15.8M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$4.4M
Typical spread (median absolute deviation)
$2.2M
How far from its usual level
+3.6
Same quarter last year
$2.2M
History used
1,461 days
2022-03-31: $7.5M2022-06-30: $4.4M2022-09-30: $4.3M2022-12-31: $4.6M2023-03-31: $2.2M2023-06-30: $1.6M2023-09-30: $2.2M2023-12-31: $14.0M2024-03-31: $15.8M
the quarter ended 31 Mar 20248 earlier quartersnormal: $4.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 15 May 2024

Sana Biotechnology saw 36 13F filers open a new position in the quarter ended 31 Mar 2024, 3.3× the same quarter last year.

This period
36 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
13
Typical spread (median absolute deviation)
2
How far from its usual level
+7.7
Same quarter last year
11
History used
1,096 days
2022-03-31: 202022-06-30: 132022-09-30: 132022-12-31: 112023-03-31: 112023-06-30: 112023-09-30: 172023-12-31: 182024-03-31: 36
the quarter ended 31 Mar 20248 earlier quartersnormal: 13

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 24 Apr 2026Filings record

    Director or officer change

  2. 17 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 17 Feb 2026Filings record

    Director or officer change

  4. 5 Sep 2025Filings record

    Director or officer change

  5. 29 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 29 Aug 2025Filings record

    Director or officer change

  7. 28 Jan 2025Short interest and volume change

    had 50.3M shares sold short in the 15 Jan 2025 report, 2.5× the same report last year.

    Same report last year: 20.2M; its normal report is 27.3M.

    See the evidence
    This period
    50.3M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    27.3M
    Typical spread (median absolute deviation)
    4.3M
    How far from its usual level
    +3.6
    Same report last year
    20.2M
    History used
    1,433 days
    2024-01-12: 20.2M2024-01-31: 21.4M2024-02-15: 22.1M2024-02-29: 21.1M2024-03-15: 24.7M2024-03-28: 26.1M2024-04-15: 26.7M2024-04-30: 25.7M2024-05-15: 25.5M2024-05-31: 25.0M2024-06-14: 24.4M2024-06-28: 26.0M2024-07-15: 27.9M2024-07-31: 29.8M2024-08-15: 31.7M2024-08-30: 31.8M2024-09-13: 31.2M2024-09-30: 31.5M2024-10-15: 33.3M2024-10-31: 34.3M2024-11-15: 35.4M2024-11-29: 35.2M2024-12-13: 36.8M2024-12-31: 37.1M2025-01-15: 50.3M
    the 15 Jan 2025 report24 earlier reportsnormal: 27.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 8 Oct 2024Filings record

    Director or officer change

  9. 12 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 12 Sep 2024Filings record

    Director or officer change

  11. 21 May 2024several at once

    spent $15.8M on capital projects in the quarter ended 31 Mar 2024, 7.3× the same quarter last year, while it saw 36 13F filers open a new position in the quarter ended 31 Mar 2024, 3.3× the same quarter last year. Two unrelated kinds of activity within 7 days.

    See the evidence (2 changes)

    Financials: Quarterly capital spending jump became public on 14 May 2024

    Sana Biotechnology spent $15.8M on capital projects in the quarter ended 31 Mar 2024, 7.3× the same quarter last year.

    This period
    $15.8M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $4.4M
    Typical spread (median absolute deviation)
    $2.2M
    How far from its usual level
    +3.6
    Same quarter last year
    $2.2M
    History used
    1,461 days
    2022-03-31: $7.5M2022-06-30: $4.4M2022-09-30: $4.3M2022-12-31: $4.6M2023-03-31: $2.2M2023-06-30: $1.6M2023-09-30: $2.2M2023-12-31: $14.0M2024-03-31: $15.8M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $4.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 15 May 2024

    Sana Biotechnology saw 36 13F filers open a new position in the quarter ended 31 Mar 2024, 3.3× the same quarter last year.

    This period
    36 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    13
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +7.7
    Same quarter last year
    11
    History used
    1,096 days
    2022-03-31: 202022-06-30: 132022-09-30: 132022-12-31: 112023-03-31: 112023-06-30: 112023-09-30: 172023-12-31: 182024-03-31: 36
    the quarter ended 31 Mar 20248 earlier quartersnormal: 13

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  12. 15 May 2024Institutional holdings change

    saw 36 13F filers open a new position in the quarter ended 31 Mar 2024, 3.3× the same quarter last year.

    Same quarter last year: 11; its normal quarter is 13.

    See the evidence
    This period
    36 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    13
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +7.7
    Same quarter last year
    11
    History used
    1,096 days
    2022-03-31: 202022-06-30: 132022-09-30: 132022-12-31: 112023-03-31: 112023-06-30: 112023-09-30: 172023-12-31: 182024-03-31: 36
    the quarter ended 31 Mar 20248 earlier quartersnormal: 13

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 14 May 2024Financials change

    spent $15.8M on capital projects in the quarter ended 31 Mar 2024, 7.3× the same quarter last year.

    Same quarter last year: $2.2M; its normal quarter is $4.4M.

    See the evidence
    This period
    $15.8M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $4.4M
    Typical spread (median absolute deviation)
    $2.2M
    How far from its usual level
    +3.6
    Same quarter last year
    $2.2M
    History used
    1,461 days
    2022-03-31: $7.5M2022-06-30: $4.4M2022-09-30: $4.3M2022-12-31: $4.6M2023-03-31: $2.2M2023-06-30: $1.6M2023-09-30: $2.2M2023-12-31: $14.0M2024-03-31: $15.8M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $4.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  14. 18 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 18 Apr 2024Filings record

    Director or officer change

  16. 5 Mar 2024Financials change

    spent $14.0M on capital projects in the quarter ended 31 Dec 2023, 3.1× the same quarter last year.

    Same quarter last year: $4.6M; its normal quarter is $4.4M.

    See the evidence
    This period
    $14.0M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $4.4M
    Typical spread (median absolute deviation)
    $1.5M
    How far from its usual level
    +4.4
    Same quarter last year
    $4.6M
    History used
    1,370 days
    2021-12-31: $5.2M2022-03-31: $7.5M2022-06-30: $4.4M2022-09-30: $4.3M2022-12-31: $4.6M2023-03-31: $2.2M2023-06-30: $1.6M2023-09-30: $2.2M2023-12-31: $14.0M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $4.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 13 Feb 2024Insiders record

    Burow Kristina (ten percent owner) and 3 other(s) bought 1,818,181 shares of SANA [same transaction as an earlier filing] (dated 12 Feb 2024)

  18. 13 Feb 2024Insiders record

    ARCH Venture Fund X, L.P. (ten percent owner) and 9 other(s) bought 1,818,181 shares of SANA ($10.0M) (dated 12 Feb 2024)

  19. 13 Feb 2024Insiders record

    NELSEN ROBERT (director) bought 1,818,181 shares of SANA [same transaction as an earlier filing] (dated 12 Feb 2024)

  20. 10 Oct 2023Filings record

    Restructuring costs announced

  21. 21 Aug 2023Filings record

    A major agreement ended

  22. 28 Apr 2023Filings record

    Director or officer change

  23. 10 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 10 Apr 2023Filings record

    Director or officer change

  25. 18 Feb 2023Insiders record

    Bilenker Joshua H. (director) bought 20,000 shares of SANA ($500,000) (dated 17 Feb 2023)

  26. 29 Nov 2022Filings record

    Restructuring costs announced

  27. 11 May 2022Short interest and volume change

    had 18.0M shares sold short in the 29 Apr 2022 report, 5.0× the same report last year.

    Same report last year: 3.6M; its normal report is 7.6M.

    See the evidence
    This period
    18.0M (the 29 Apr 2022 report)
    Normal report (median of 24 earlier)
    7.6M
    Typical spread (median absolute deviation)
    1.9M
    How far from its usual level
    +3.6
    Same report last year
    3.6M
    History used
    441 days
    2021-04-15: 3.3M2021-04-30: 3.6M2021-05-14: 3.4M2021-05-28: 3.4M2021-06-15: 3.5M2021-06-30: 5.6M2021-07-15: 6.2M2021-07-30: 6.6M2021-08-13: 6.4M2021-08-31: 6.5M2021-09-15: 6.4M2021-09-30: 8.4M2021-10-15: 8.4M2021-10-29: 8.1M2021-11-15: 8.0M2021-11-30: 7.4M2021-12-15: 7.9M2022-01-14: 9.5M2022-01-31: 11.2M2022-02-15: 13.0M2022-02-28: 13.5M2022-03-15: 13.7M2022-03-31: 16.4M2022-04-14: 17.7M2022-04-29: 18.0M
    the 29 Apr 2022 report24 earlier reportsnormal: 7.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 27 Apr 2022Short interest and volume change

    had 17.7M shares sold short in the 14 Apr 2022 report, 5.3× the same report last year.

    Same report last year: 3.3M; its normal report is 7.0M.

    See the evidence
    This period
    17.7M (the 14 Apr 2022 report)
    Normal report (median of 24 earlier)
    7.0M
    Typical spread (median absolute deviation)
    2.0M
    How far from its usual level
    +3.7
    Same report last year
    3.3M
    History used
    426 days
    2021-03-31: 2.6M2021-04-15: 3.3M2021-04-30: 3.6M2021-05-14: 3.4M2021-05-28: 3.4M2021-06-15: 3.5M2021-06-30: 5.6M2021-07-15: 6.2M2021-07-30: 6.6M2021-08-13: 6.4M2021-08-31: 6.5M2021-09-15: 6.4M2021-09-30: 8.4M2021-10-15: 8.4M2021-10-29: 8.1M2021-11-15: 8.0M2021-11-30: 7.4M2021-12-15: 7.9M2022-01-14: 9.5M2022-01-31: 11.2M2022-02-15: 13.0M2022-02-28: 13.5M2022-03-15: 13.7M2022-03-31: 16.4M2022-04-14: 17.7M
    the 14 Apr 2022 report24 earlier reportsnormal: 7.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 23 Mar 2022Insiders record

    Yang Patrick Y (director) bought 28,000 shares of SANA ($204,400) (dated 22 Mar 2022)

  30. 3 Sep 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 3 Sep 2021Filings record

    Director or officer change

  32. 14 May 2021Institutional holdings record

    FMR LLC opened a $292.0M position (2021Q1 13F)

  33. 6 May 2021Institutional holdings record

    BAILLIE GIFFORD & CO opened a $334.0M position (2021Q1 13F)

  34. 2 Mar 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 2 Mar 2021Filings record

    Director or officer change

  36. 3 Feb 2021Filings record

    Registered new securities for sale (S-1)

  37. 2 Feb 2021Filings record

    Registered new securities for sale (S-1) (dated 1 Feb 2021)

  38. 28 Jan 2021Filings record

    Registered new securities for sale (S-1)

  39. 13 Jan 2021Filings record

    Registered new securities for sale (S-1) (dated 12 Jan 2021)

  40. 26 Jun 2020Filings record

    Private placement of securities (Form D)

Showing the newest 40 of 41 entries; narrow the window or the kind of data to see older ones.

Not listed: 85 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001770121
Ticker
SANA
Domain
sana.com
Employer name
Sana Biotechnology, Inc. (1 unverified)
Hq location
WA|SEATTLE| (1 unverified)
Name
Sana Biotechnology, Inc.
Wikidata
Q106301980
  • DOL H-1B labor condition applications and PERM certifications321 data points3 Feb 2020 to 31 Aug 2026
  • SEC Form 13F institutional holdings2 records, 207 data points31 Mar 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)92 records26 Jun 2020 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)377 data points31 Dec 2018 to 29 Oct 2026
  • SEC Form 4 insider transactions18 records, 64 data points1 Sep 2021 to 10 Jan 2025
  • FINRA short interest (twice monthly)410 data points12 Feb 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2914 data points4 Feb 2021 to 20 Nov 2026